An­oth­er Langer-backed biotech breaks out of stealth mode, aims for the clin­ic with hear­ing loss ther­a­py

Over the last 18 months the team at Fre­quen­cy Ther­a­peu­tics’ Kendall Square of­fice has been mak­ing qui­et progress with its pre­clin­i­cal work on a new ap­proach to cur­ing hear­ing loss, ex­plor­ing the po­ten­tial of a ther­a­peu­tic tech­nique that emerged out of the lab of MIT’s se­r­i­al sci­ence en­tre­pre­neur Bob Langer and his col­league Jeff Karp. To­day, though, the stealthy ramp-up is over as the biotech de­buts its man­age­ment team and R&D strat­e­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER